This is an open,observational and follow-up clinical trial based on the clinical trial of EV71 vaccine extended age group.The purpose of this study is to evaluate the immunity persistence of EV71 vaccine developed by Sinovac Biotech Co., Ltd in subjects aged 6 \~71 months after full immunization of two doses of vaccine.
This study is an open,observational and follow-up clinical trial of EV71 vaccine based on the clinical trial of EV71 vaccine extended age group.The main purpose of this study is to evaluate the immunity persistence of EV71 vaccine developed by Sinovac Biotech Co., Ltd in subjects aged 6\~71 months after full immunization of two doses of vaccine.In this study, a total of 474 subjects from the EV71 vaccine extended age clinical trial who received two doses of experimental or control vaccine and were enrolled in the PPS set,including 274 subjects aged 6\~35 months (the maximum number of subjects aged 6-23 months is 146, and the maximum number of subjects aged 24-35 months is 128),100 subjects aged 36\~71 months and were enrolled in experimental group(EV71 vaccine developed by Sinovac Biotech Co., Ltd) and 100 subjects aged 36\~71 months and were enrolled in control group(EV71 vaccine developed by Institute of Medical Biology,Chinese Academy of Medical Sciences) will be enrolled .Blood samples will be collected from subjects aged 6-23 months at 36 months after full immunization and at the age of 72 months.Blood samples will be collected from subjects aged 24 to 35 months at 36 months after full immunization.Blood samples will be collected from subjects aged 36-71 months at 36 months after the full immunization.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
474
The EV71 vaccine was manufactured by Sinovac Biotech Co., Ltd and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
The EV71 vaccine was manufactured by Institute of Medical Biology,Chinese Academy of Medical Sciences ,and inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
Yun County Center for Disease Control and Prevention
Lincang, Yunnan, China
The seroconversion rates (SCR) of EV71 neutralizing antibody of all enrolled subjects
The seroconversion rates (SCR) of EV71 neutralizing antibody of all subjects at 36 months after full immunization.
Time frame: At 36 months after full immunization
The seroconversion rates (SCR) of the EV71 neutralizing antibody of subjects aged 6-23 months
The seroconversion rates (SCR) of the EV71 neutralizing antibody of subjects aged 6-23 months at the age of 72months.
Time frame: At the age of 72 months
GMT of the EV71 neutralizing antibody of all enrolled subjects
GMT of the EV71 neutralizing antibody of all enrolled subjects at 36 months after full immunization.
Time frame: At 36 months after full immunization
GMT of the EV71 neutralizing antibody of subjects aged 6-23 months
GMT of the EV71 neutralizing antibody of subjects aged 6-23 months at the age of 72months.
Time frame: At the age of 72 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.